A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study

Key facts

Sponsor

Power Life Sciences Inc.

Principal Investigator

Michael B Gill

Power Life Sciences Inc.

Enrollment

500 target

Eligibility

18 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• Power Life Sciences, San Francisco, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Medullary thyroid carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07383246
  CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• RECRUITINGNCT07142005
  Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer
  M.D. Anderson Cancer Center
• RECRUITINGNANCT07138716
  Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
  Luo Yaping
• ENROLLING BY INVITATIONNCT06852144
  PET-TC in Thyroid Evaluation
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• RECRUITINGNANCT06141369
  Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
  Shanghai Jiao Tong University School of Medicine
• RECRUITINGNANCT06277180
  68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• RECRUITINGPHASE1NCT06520319
  Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
  First Affiliated Hospital of Fujian Medical University
• RECRUITINGPHASE4NCT05830500
  Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

See all trials for Medullary thyroid carcinoma →